CTNI-35. SURVIVAL BENEFIT OF ADDING OSIMERTINIB TO STANDARD SALVAGE TREATMENT REGIMENS FOR RECURRENT GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ALTERATIONS
CTNI-35. 在表皮生长因子受体 (EGFR) 改变的复发性胶质母细胞瘤 (GBM) 的标准挽救治疗方案中加入奥西替尼的生存获益
期刊:Diagnostics
影响因子:3.3
doi:10.3390/diagnostics15091091
Qiu, Shawn; Hadidchi, Roham; Vichare, Aditi; Lu, Justin Y; Hou, Wei; Henry, Sonya; Akalin, Enver; Duong, Tim Q; Chen, Zhihua; Sinha, Mousumi; Nahm, Josh; Hsu, Sigmund; Esquenazi, Yoshua; Tandon, Nitin; Amsbaugh, Mark; Blanco, Angel; Ware, Cornelius; Lu, Austin; Zhu, Jay-Jiguang